Abstract 5882: A novel NGS-based assay in kit format for tumor-independent cancer monitoring, and evaluation of patient treatment response using cfDNA genomic alteration and methylation duo analysis

作者：Tali Azenkot, Grace Zhao, Heng Wang, Xiaomu Chen, Margherita Corioni, Michael Ruvolo, Teressa Celma, Jeff Pawelek, Aswati Aravind, Douglas Roberts, Yun Bao, Bram Herman, Annie A. Wu, William M. Mitchell, Kathryn A. Gold, Lyudmila Bazhenova, Shengrong Lin, Sandip H. Patel · 发表于：Cancer Research · 年份：2025 · DOI：10.1158/1538-7445.am2025-5882 · 研究领域：Cancer Genomics and Diagnostics、Radiomics and Machine Learning in Medical Imaging、Molecular Biology Techniques and Applications

Abstract Introduction: While circulating tumor DNA-based tests have shown promise in evaluating treatment response, predicting prognosis, and detecting measurable residual disease, tumor-informed personalized strategies have limitations. For example, the need for large tumor samples and the complexity and high cost of personalized testing can be barriers to clinical use. Commercially available genomic and methylation tumor-independent assays require large panels and sample splitting, further limiting their practicality. Both these assays require samples to be sent to centralized CLIA-certified labs. To address these challenges, we explored the Agilent Avida target enrichment technology in a small sample of patients with non-small cell lung cancer (NSCLC). This kit-based solution reduces sequencing costs, is compatible with automation systems like the Agilent Bravo NGS Workstation, and enables decentralized, faster molecular analysis. Methods: We applied the Agilent Avida circulating cell-free DNA (cfDNA) genomic alteration and methylation combined analysis for tumor-independent cancer monitoring in patients with NSCLC. First, we demonstrated the differential hypermethylation cancer-specific signal in 4 different lung cancer tumors, with low background noise in normal lung tissues, non-cancerous pathological lung tissue, control peripheral blood mononuclear cells, and cfDNA. We then showed feasibility of this cfDNA technology in patients with stage I through III NSCLC. In 4 pa...